DIAPH1 Antibody

What is DIAPH1 and why is it important in scientific research?

DIAPH1 functions as an actin nucleation and elongation factor required for the assembly of F-actin structures such as actin cables and stress fibers. It binds to the barbed end of actin filaments and regulates both polymerization and depolymerization processes . DIAPH1 is critical for multiple cellular functions including cytokinesis, transcriptional activation, and microtubule stabilization.

Research interest in DIAPH1 has intensified due to its association with several pathological conditions:

• Autosomal dominant nonsyndromic sensorineural hearing loss (DFNA1)

• Macrothrombocytopenia with hearing loss

• Immunodeficiency affecting T cells, NK cells, and ILCs

• Contributions to atherosclerosis progression

• Regulation of mitochondria-SR/ER contact sites through interaction with MFN2

These diverse functions make DIAPH1 a significant target for researchers studying cytoskeletal dynamics, cellular differentiation, and various disease mechanisms.

What types of DIAPH1 antibodies are available for research applications?

Most commercially available DIAPH1 antibodies are rabbit polyclonals recognizing different epitopes. These include antibodies targeting specific domains which can be particularly useful when studying truncation mutations or protein interactions. The antibodies typically come in liquid form containing preservatives such as sodium azide and glycerol .

What are the recommended applications and dilutions for DIAPH1 antibodies?

Based on validated research applications, DIAPH1 antibodies can be used in multiple experimental approaches:

• Western Blotting (WB): Recommended dilutions range from 1:500-1:2000 . DIAPH1 typically appears as a band at approximately 141-155 kDa, with potential proteolytic fragments at ~80 kDa in some samples .

• Immunofluorescence (IF): Recommended dilutions range from 1:50-1:100 . This technique is useful for visualizing DIAPH1 subcellular localization, which varies by cell type. For instance, in resting platelets, DIAPH1 localizes to the peripheral marginal band .

• Immunohistochemistry (IHC): Both paraffin-embedded and frozen section protocols have been validated . DIAPH1 expression has been demonstrated in human atherosclerotic plaques, co-localizing with macrophage and smooth muscle cell markers .

• Immunoprecipitation (IP): Essential for studying protein interactions, such as the DIAPH1-MFN2 interaction . IP with DIAPH1 antibodies followed by Western blotting for interacting partners helps elucidate DIAPH1's functional networks.

• Proximity Ligation Assay (PLA): Used to study endogenous protein-protein interactions in cells and fixed tissues, as demonstrated for DIAPH1-MFN2 interactions .

How can I optimize immunofluorescence protocols for DIAPH1 detection?

Optimizing immunofluorescence for DIAPH1 requires careful consideration of several parameters:

• Fixation method: Paraformaldehyde fixation is commonly used for DIAPH1 immunofluorescence, as demonstrated in validated ICC protocols for LOVO cells .

• Co-staining strategies: For comprehensive cytoskeletal analysis, combine:

  • DIAPH1 antibody staining

  • Phalloidin-Atto647N for F-actin visualization

  • Anti-tubulin antibodies for microtubule detection

  • DAPI for nuclear counterstaining

• Cell-specific considerations: DIAPH1 localization varies significantly between cell types:

  • In platelets: Localizes to peripheral marginal band in normal samples but is disorganized in platelets with DIAPH1 mutations

  • In cultured cell lines: May show distinct localization patterns based on activation state

• Dynamic experimental designs: For studying DIAPH1's role in cytoskeletal dynamics, temperature manipulation protocols can reveal functional properties. For example, cold incubation (4°C) followed by rewarming (37°C) demonstrates microtubule stability differences between normal and DIAPH1 mutant platelets .

• Controls: Include positive controls (cells known to express DIAPH1) and negative controls (either DIAPH1 knockdown cells or primary antibody omission).

How do I troubleshoot Western blot issues when detecting DIAPH1?

When troubleshooting DIAPH1 Western blots, consider these research-validated approaches:

• Sample preparation considerations:

  • Anticoagulant effects: Research has shown different results between EDTA and acid citrate dextrose anticoagulation for platelet samples

  • Protein degradation: Include protease inhibitors during lysate preparation

  • Loading control selection: GAPDH, α-tubulin, and other standard loading controls have been validated

• Antibody optimization:

  • Dilution series: Test a range around the recommended 1:500-1:2000 dilution

  • Incubation conditions: Optimize temperature and duration based on signal intensity

  • Antibody selection: For mutation studies, carefully consider epitope location relative to mutation sites

• Detection challenges:

  • Expected bands: Primary band at ~155 kDa (full-length DIAPH1) with possible secondary band at ~80 kDa (proteolytic fragment)

  • Band separation: For detecting small truncations like R1213*, lower percentage acrylamide gels may improve resolution

  • Signal enhancement: Extended exposure times may be necessary for detecting low expression levels

• Validation approaches:

  • Multiple antibodies: When possible, confirm results using antibodies targeting different DIAPH1 epitopes

  • Knockout/knockdown controls: shRNA knockdown of DIAPH1 provides essential negative controls

  • Advanced confirmation: Immunoprecipitation followed by mass spectrometry can verify band identity

How can I detect both wild-type and mutant DIAPH1 proteins in experimental samples?

Detection of wild-type and mutant DIAPH1 variants presents specific challenges, particularly with disease-associated mutations:

• Antibody selection strategy:

  • For C-terminal truncation mutations (R1213*, R1204X): Use antibodies targeting N-terminal epitopes that are preserved in both wild-type and mutant proteins

  • For N-terminal truncation mutations (R351*, R322*): Consider antibodies against C-terminal regions if protein expression occurs despite nonsense-mediated decay

• Expression verification approaches:

  • Protein level: Western blotting and immunofluorescence microscopy

  • mRNA level: RT-qPCR to assess transcript levels and potential nonsense-mediated decay

  • Flow cytometry: Has been successfully used to quantify DIAPH1 protein levels in patient cells

• Distinguishing wild-type from mutant proteins:

  • For R1213* mutation: The truncated protein may not be clearly distinguishable from wild-type by size alone in standard Western blots

  • For more substantial truncations: Size separation on gradient gels may reveal distinct bands

  • For subtle mutations: May require specialized approaches like mass spectrometry

• Functional readouts:

  • Subcellular localization: Constitutively active mutants show distinct localization patterns

  • Cytoskeletal organization: Mutants often show altered F-actin and microtubule organization detectable by immunofluorescence

How do I design experiments to study DIAPH1-MFN2 interaction using antibody-based approaches?

The interaction between DIAPH1 and Mitofusin-2 (MFN2) has important implications for mitochondria-ER contact sites. Based on published methodologies, here's a comprehensive approach:

• Co-immunoprecipitation protocol:

  • Cell model: HiPSC-CMs (human induced pluripotent stem cell-derived cardiomyocytes) have been validated

  • Experimental conditions: Hypoxia/reoxygenation (H/R) treatment enhances detection of the interaction

  • Primary IP: Use anti-DIAPH1 antibodies for pull-down, followed by Western blotting with anti-MFN2 antibodies

  • Reciprocal IP: Use anti-MFN2 antibodies for pull-down, followed by Western blotting with anti-DIAPH1 antibodies

  • Specificity controls: Include IgG control IPs and verify absence of interaction with related proteins (e.g., DIAPH1 does not interact with MFN1)

• Proximity Ligation Assay (PLA):

  • The DUOLINK® PLA system has been validated for studying endogenous DIAPH1-MFN2 interactions

  • Requires primary antibodies raised in different species (e.g., rabbit anti-DIAPH1 and mouse anti-MFN2)

  • Provides spatial information about interaction sites within cells

  • Quantification: Number of PLA puncta indicates interaction frequency

• Domain mapping studies:

  • For identifying specific interaction domains, create truncated versions of DIAPH1 and MFN2

  • Express tagged protein domains and perform pull-down assays, similar to the GST-DID and biotin-DAD approach used for studying DID-DAD interactions

  • Mutation analysis: Create point mutations in candidate interaction regions to disrupt binding

• Functional correlation:

  • Correlate interaction strength with phenotypic outcomes

  • Measure mitochondria-ER contact sites using microscopy techniques

  • Assess effects of DIAPH1 knockdown or mutation on these contacts

What are optimal methods for studying DIAPH1 in platelets and megakaryocytes?

Research on DIAPH1 in platelets and megakaryocytes requires specialized approaches due to their unique biology:

• Platelet isolation and analysis:

  • Anticoagulant selection: Critical for consistent results; both EDTA and acid citrate dextrose have been used with different outcomes

  • Microscopy preparation: Apply platelets to fibrinogen-coated coverslips for adhesion before fixation

  • Cytoskeletal visualization:

    • Triple staining with DIAPH1 antibody, phalloidin (F-actin), and anti-tubulin antibodies

    • Electron microscopy for detailed ultrastructural analysis of microtubule organization

• Dynamic cytoskeletal assays:

  • Microtubule stability assessment: Cold incubation (4°C) followed by rewarming (37°C) reveals differences between normal and mutant platelets

  • Quantification: Manual counting of microtubule coils in platelets (approximately 2.6-fold more coils in R1213* mutant platelets)

  • Drug treatments: Colchicine preincubation can be used as control for microtubule disruption

• Megakaryocyte culture and differentiation:

  • Cell source: CD34+ hematopoietic stem cells isolated from peripheral blood

  • Culture systems:

    • Plate cultures for colony-forming unit-megakaryocyte (CFU-MK) assays

    • Liquid cultures for differentiation studies and proplatelet formation assessment

  • Visualization: May-Grünwald-Giemsa stain, phalloidin, or anti-CD61 antibodies

  • Functional assays: Proplatelet formation quantification by light microscopy; ploidy analysis by flow cytometry

• Expression studies:

  • For examining mutant DIAPH1 effects: Generate site-directed mutants (e.g., R1213*) in expression vectors

  • Cell models: HEK293FT and A549 cells have been validated for transient transfection

  • Detection: Western blotting and immunofluorescence microscopy using anti-DIAPH1 antibodies

How can I detect and characterize constitutively active DIAPH1 mutants?

Constitutively active DIAPH1 mutants, particularly those with disrupted autoinhibition, can be detected and characterized through multiple approaches:

• Biochemical assessment of autoinhibition:

  • Pull-down assays using GST-tagged DID and biotin-tagged DAD domains

  • Quantify interaction strength: Weaker DID-DAD interaction indicates constitutive activation

  • Controls: Include known activating mutations like M1190D for comparison

• Subcellular localization analysis:

  • Immunofluorescence microscopy: Constitutively active DIAPH1 shows enhanced plasma membrane localization

  • Quantification: Calculate percentage of DIAPH1 at plasma membrane versus cytoplasmic distribution

  • Comparison: The degree of plasma membrane localization correlates with activation level (e.g., DIA1(RRKR 1204–1207/EEEEX) ≥ DIA1(RRKR 1204–1207/EEEX) > DIA1(RRKR 1204–1207/EEX) > DIA1(RRKR 1204–1207/EX) > DIA1(R1204X) > WT DIA1)

• Functional readouts of constitutive activation:

  • F-actin assembly: Increased phalloidin staining in cells expressing active mutants

  • Microtubule organization:

    • Increased α-tubulin staining

    • Aberrant microtubule organization

    • Resistance to cold-induced disassembly

  • Proplatelet formation: Reduced in megakaryocytes expressing constitutively active DIAPH1

• Dynamic activity assessment:

  • Fluorescence single-molecule speckle microscopy (SiMS): Detects processive movement of constitutively active DIAPH1

  • Live-cell imaging: Reveals altered dynamics compared to wild-type protein

• Disease-relevant mutations:

  • R1213* mutation: Causes truncation prior to the basic RRKR motif in the DAD domain

  • R1204X mutation: Similar truncation removing the RRKR motif

  • These mutations disrupt the autoinhibitory DID-DAD interaction, resulting in constitutive activation

How can DIAPH1 antibodies be used to study immune cell functions?

Recent research has revealed critical roles for DIAPH1 in immune cell development and function, particularly in T cells, NK cells, and innate lymphoid cells (ILCs):

• T cell functional studies:

  • Activation assays: DIAPH1-deficient T cells show impaired proliferation and reduced expression of activation markers (CD25, CD69) after stimulation with CD3/28 or PHA

  • Signaling analysis: Western blotting with phospho-specific antibodies reveals impaired TCR signaling components (ZAP70, NF-κB) in DIAPH1-knockdown Jurkat cells

  • Cytokine production: Assessment of IL-2 production and STAT5 activation pathway

• NK cell analysis protocols:

  • Cytotoxicity assays: DIAPH1-deficient NK cells show diminished cytotoxic activity

  • Functional assessment: Multiparameter flow cytometry and stimulation assays

  • IL-2/STAT5 axis evaluation: Similar impairments to those observed in T cells

• ILC subset quantification:

  • Flow cytometry: DIAPH1-deficient patients show dramatically reduced numbers of all helper ILC subsets

  • Phenotypic characterization: Surface marker and transcription factor analysis

• DIAPH1 knockdown approaches:

  • shRNA constructs with GFP reporters in Jurkat T cell line

  • Verification of knockdown: Western blot and RT-qPCR analysis

  • Controls: Multiple shRNA constructs should be tested for consistency and specificity

• Patient-derived samples:

  • Genotype correlation: Compare functional defects across different DIAPH1 mutations (e.g., p.R351*, p.R322*)

  • Comprehensive immune phenotyping: Multiparameter flow cytometry for immune cell subset analysis

How can I investigate DIAPH1's role in atherosclerosis progression?

DIAPH1 has been implicated in atherosclerosis progression, with expression in both human and mouse atherosclerotic lesions:

• Expression analysis in atherosclerotic tissue:

  • Immunohistochemistry protocols: DIAPH1 antibodies successfully detect expression in human and mouse atherosclerotic plaques

  • Co-localization studies: DIAPH1 co-localizes with CD68 (macrophages) and Smooth Muscle Actin (SMCs) in atherosclerotic lesions

  • Controls: Compare expression between atherosclerotic and normal vessel walls

• Animal model systems:

  • Ldlr−/− mice fed a Western diet (WD) for 16 weeks develop atherosclerotic lesions with DIAPH1 expression

  • Genetic manipulation: DIAPH1 knockout or conditional deletion in atherosclerosis-prone backgrounds

  • Analysis timepoints: Multiple timepoints during diet feeding to track progression

• Cellular mechanisms assessment:

  • Macrophage function: Lipid uptake, foam cell formation, inflammatory responses

  • Smooth muscle cell behavior: Migration, proliferation, phenotypic switching

  • Endothelial cell studies: Barrier function, inflammatory activation

• RAGE-DIAPH1 signaling axis:

  • As DIAPH1 binds to the RAGE cytoplasmic domain and is important for RAGE signaling , investigate this pathway in atherosclerosis

  • Co-immunoprecipitation studies to confirm interaction in atherosclerosis-relevant cells

  • Inhibition strategies: Target specific domains or interactions

• Translational approaches:

  • Patient sample correlation: Compare DIAPH1 expression levels with atherosclerosis severity

  • Biomarker potential: Assess circulating markers associated with DIAPH1 activity